In vivo gene transfer targeting in pancreatic adenocarcinoma with cell surface antigens by Marie Lafitte et al.
Lafitte et al. Molecular Cancer 2012, 11:81
http://www.molecular-cancer.com/content/11/1/81RESEARCH Open AccessIn vivo gene transfer targeting in pancreatic
adenocarcinoma with cell surface antigens
Marie Lafitte1,2, Benoit Rousseau3, Isabelle Moranvillier1,2, Miguel Taillepierre1,2, Evelyne Peuchant1,2,
Véronique Guyonnet-Dupérat2,4, Aurélie Bedel1,2, Pierre Dubus2, Hubert de Verneuil1,2,
François Moreau-Gaudry1,2,4,5*† and Sandrine Dabernat1,2†Abstract
Background: Pancreatic ductal adenocarcinoma is a deadly malignancy resistant to current therapies. It is critical to
test new strategies, including tumor-targeted delivery of therapeutic agents. This study tested the possibility to
target the transfer of a suicide gene in tumor cells using an oncotropic lentiviral vector.
Results: Three cell surface markers were evaluated to target the transduction of cells by lentiviruses pseudotyped
with a modified glycoprotein from Sindbis virus. Only Mucin-4 and the Claudin-18 proteins were found efficient for
targeted lentivirus transductions in vitro. In subcutaneous xenografts of human pancreatic cancer cells models,
Claudin-18 failed to achieve efficient gene transfer but Mucin-4 was found very potent. Human pancreatic tumor
cells were modified to express a fluorescent protein detectable in live animals by bioimaging, to perform a direct
non invasive and costless follow up of the tumor growth. Targeted gene transfer of a bicistronic transgene bearing
a luciferase gene and the herpes simplex virus thymidine kinase gene into orthotopic grafts was carried out with
Mucin-4 oncotropic lentiviruses. By contrast to the broad tropism VSV-G carrying lentivirus, this oncotropic lentivirus
was found to transduce specifically tumor cells, sparing normal pancreatic cells in vivo. Transduced cells
disappeared after ganciclovir treatment while the orthotopic tumor growth was slowed down.
Conclusion: This work considered for the first time three aspect of pancreatic adenocarcinoma targeted therapy.
First, lentiviral transduction of human pancreatic tumor cells was possible when cells were grafted orthotopically.
Second, we used a system targeting the tumor cells with cell surface antigens and sparing the normal cells. Finally,
the TK/GCV anticancer system showed promising results in vivo. Importantly, the approach presented here
appeared to be a safer, much more specific and an as efficient way to perform gene delivery in pancreatic tumors,
in comparison with a broad tropism lentivirus. This study will be useful in future designing of targeted therapies for
pancreatic cancer.
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Pancreatic ductal adenocarcinoma (PDAC) is a highly
malignant disease and is the fourth cause of death from
cancer in the western world. Due to the lack of specific
symptoms, the diagnosis is delayed and PDAC are com-
monly detected at advanced stages of the disease.
Regardless of the treatment, the 5-year survival is less
than 5% [1]. Surgical resection offers the best chances of* Correspondence: francois.moreau-gaudry@u-bordeaux2.fr
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reproduction in any medium, provided the orsurvival at the time of the diagnosis, but is curative in
only 13% of the cases and is possible for only 15% of the
patients. Moreover, even resectable PDACs display a
high rate of recurrence [1]. Systemic chemotherapy still
relies on the pyrimidine analog gemcitabine because it
has been the only drug producing symptoms improve-
ment, raising the overall 1-year survival from 2% to
around 18% of the patients. Extensive efforts have been
made to identify adjuvant or neoadjuvant therapies cap-
able of improving the poor prognosis of PDAC, based
on the molecular targets involved in cancer progression.
Unfortunately, phase III studies have shown limited ortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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with gemcitabine [1]. In fact, PDAC presents very com-
plex genetic alterations profiles explaining the failure of
single gene/pathway targeted adjuvant therapies. Indeed,
the Pancreatic Cancer Genome project has analyzed
23,219 transcripts and identified an average of 63 som-
atic mutations per PDAC affecting 12 core signaling
pathways and the overexpression of 500 different genes
in 24 tumors [2].
Thus, it is now critical to test therapies targeting sev-
eral pathways or therapies inducing specific tumor cell
death [3]. In that aspect, cytoreductive therapy inducing
direct cell death rather than corrective therapy aimed at
repairing genetic defects involved in malignancy should
be preferred for PDAC, because of the general resistance
of tumor cells against therapeutic agents. In that regard,
gene therapy remains an attractive option to transfer sui-
cide genes [4-6]. Specific efficient expression of suicide
genes in tumor cells is currently achieved by designing
vectors containing tissue-specific promoters. Moreover,
suicide genes are chosen to be able to induce bystander
killing of cancer cells in the vicinity of gene-modified
(transduced) cancer cells [5]. Disappointing results how-
ever, have been obtained in phase I/II trials with adeno-
viruses or retroviruses, but studies are still focusing on
improving this treatment conditions [3]. Over the
numerous means to perform in vivo gene delivery,
increasing interest has been shown in lentiviral vectors
because they can infect non-dividing cells and display
high gene delivery efficiency. Previous studies have
shown the feasibility of gene therapy in PDAC [7-9] with
diverse efficiencies of gene transfer. Lentivectors are
commonly packaged into viral envelopes exhibiting
glycoproteins with a broad tropism, such as Vesicular
Stomatitis Virus-Glycoprotein (VSV-G). It is however
important to restrain the infectious capacity of thera-
peutic vectors to the tumor cells only, limiting side
effects on the neighboring normal cells. Cell-specific tar-
geting has been developed using a modified envelope
displaying the IgG binding-domain of protein A, which
can bind the Fc domain of immunoglobulins. In conse-
quence, virions can be associated with cell surface-directed
antibodies to target the specific transduction of cancer cells
[10-12]. This system has given good results with in vivo
models to transduce prostate cancer bone metastasis [13],
the therapeutic gene thymidine kinase in prostate cancer
metastasis [14] and breast cancer cells [15].
To date, the possibility of specific gene transfer in
PDAC tumor cells has not been evaluated, and this study
was aimed to test the modified Sindbis virus glycopro-
tein to target PDAC cells in vivo. PDAC cell surface
antigens have been selected according to published data.
Recently, a list of biomarker candidates for PDAC has
been obtained from a comprehensive literature survey[16]. Accordingly and as previously reported [17,18], two
markers appeared appropriate for the present study
because of their localization at the cell surface and their
specific overexpression in PDAC, namely the variant 2
of Claudin-18 (CLDN18) and the Mucin-4 protein
(MUC4). The Prostate Stem Cell Antigen (PSCA) was
also included because it was used by Pariente et al. to
target prostate cancer cells with the same system [13]
and has been proposed for immune therapy [19].
In this study, specific reporter gene transfer has been
examined in vitro with antibodies directed against the
cell surface markers described above. More importantly,
in vivo targeting of pancreatic cancer cells has been
tested in subcutaneous and orthotopic xenografts mod-
els and quantitatively compared to a broad tropism
virus. Our models included the use of a grafted PDAC
cell line modified to stably express the tdTomato
reporter gene, which expression was directly monitored
in live animals by fluorescence detection. Finally, the
possibility of transferring the suicide gene thymidine
kinase has been assessed in orthotopic xenografts, which
growth was monitored by the detection of tdTomato.
Results
Targeted transduction of pancreatic cell lines in vitro
To package the lentiviruses, we used a modified Sindbis
virus glycoprotein. The E2 recognition ZZ domain of the
Sindbis virus glycoprotein has been modified to contain
the Fc-binding domain of the protein A [12]. The resulting
mutant glycoprotein was called 2.2 [13,14]. Thus, virions
can be associated with cell surface-specific antibodies to
target the transduction of tumor cells (Figure 1). They will
be referred as oncotropic. Transductional targeting was
performed using antibodies that recognize the PSCA
(Prostate stem cell antigen), the MUC4 and the Claudin
18 variant 2 antigens (CLDN18), all chosen according to
published data showing specific expression or overexpres-
sion of these proteins in pancreatic adenocarcinomas
(see Background section, Figure 1).
To test the capacity of pancreatic adenocarcinoma cell
lines to be transduced, we performed lentiviral transduc-
tions with a VSV-G pseudotyped lentiviral vector carrying
a transgene encoding the reporter gene green fluorescent
protein (GFP). Multiplicities of infection ranging from 1
to 30 (MOI1 to MOI30, corresponding to 10 ng of p24 to
300 ng of p24 for 5 × 104 cells, p24 being a viral capside
protein titrated as described in the Methods section) were
used and cells were analyzed by flow cytometry for GFP
expression 4 days after the transductions. All the cell lines
were transduced by the lentiviruses with various efficien-
cies (Figure 2A). The CAPAN1 cell line was, in our condi-
tions, more resistant to transduction than the other cell
lines tested, since the percentage of GFP-positive cells did
not reach more than 40%, at the highest MOI used. Thus,
Figure 1 Oncospecific transduction in human pancreatic tumor cells. PDAC cell surface specific antigens were chosen according to previous
reports. They were used to target lentiviral transductions of the Green Fluorescent Protein (GFP) reporter gene, using a Sindbis virus modified
glycoprotein. The E2 recognition ZZ domain of glycoprotein has been modified to contain the Fc-binding domain of the protein A. The resulting
mutant glycoprotein was called 2.2. Thus, virions can be associated with cell surface-specific antibodies to target the transduction of tumor cells (insert).
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PANC1 cells seemed moderately resistant to viral
transduction.
The pancreatic cancer cell lines were then transduced
with the oncotropic vectors (with 100 ng of p24 for 5 × 104
cells). They were also transduced with an oncotropic
lentivirus associated to an anti-HLA antibody as a posi-
tive control or associated with isotype control antibodies
(rabbit IgGs) as a negative control. Cell lines displayed ef-
ficient transduction with the positive control since at
least 30% of the cells were transduced by the viruses asso-
ciated with the anti-HLA antibody (30% for the PANC1
to 71% for the BXPC3, Figure 2B). Furthermore, the use
of anti-PSCA antibody did not achieve transduction effi-
ciencies above that of the negative control values in all
the tested lines. Conversely, values with anti-MUC4 and
anti-CLDN18 reached percentages of transduction at
least 2 times above that of the negative control, the best
results being for the anti-CLDN18 in the MIAPACA2
cells and the anti-MUC4 in the CAPAN2 cells (5 times).
We asked whether the differences in transduction effi-
ciencies were dependent on the levels of the target sur-
face antigens. Western-blots analyses showed that
the PANC1 cell line expressed the highest level of HLA
proteins (Figure 2C), but was the least efficient in trans-
duction (only 30%, Figure 2B) as already observed with
VSV-G pseudotyped lentivectors (Figure 2A). On the
other hand, the MIAPACA2 cells had a very good poten-
tial for transduction with the broad tropism virus
(Figure 2A), but showed a weaker efficiency with the
MUC4 oncotropic virus as compared with the BXPC3
and CAPAN2 cells. Western-blot analysis showed that
the MIAPACA2 did express lower levels of MUC4.Therefore, the efficiency of transduction seems to de-
pend on both the intrinsic ability of the cells to be trans-
duced and the level of expression of the cell surface
antigen targeting the oncotropic lentivirus.
Thus, the anti-CLDN18 and anti-MUC4 antibodies
displayed sufficient transductions in vitro to be further
evaluated in in vivo xenograft models with the CAPAN2
and the MIAPACA2 cells.
Targeted transduction of pancreatic cell lines in vivo
To assess the efficient transduction of the cells in vivo, the
lentiviruses were designed to express the firefly luciferase,
for which expression was detected in live animals by a
bioimaging system. In order to test the oncotropic gene
transfer in pancreatic tumor cells in vivo, CAPAN2 cells
were xenografted subcutaneously in immune-compromised
mice. Anti-MUC4 and anti-CLDN18 antibodies were con-
jugated to lentiviruses packaged into an envelope contain-
ing the modified 2.2 Sindbis virus glycoprotein and injected
directly in the tumors. Control mice were injected with
anti-HLA (positive control) or rabbit IgGs (negative con-
trol) conjugated viruses. Moreover, a group of tumor bear-
ing mice was injected with broad tropism viruses packaged
into the VSV-G-containing envelopes (positive control),
since it was previously shown to cause efficient gene trans-
fer in pancreatic adenocarcinoma [7-9]. Luciferase signals
were evaluated according to the tumor mass, since all
tumors were not equivalent within each group, and in all
groups. As expected, two weeks after the virus injections,
tumors injected with rabbit IgGs-conjugated viruses
showed gene transfer less than 2% of VSV glycoprotein-
containing viruses and the association with anti-HLA
represented about 20% of the signal obtained for VSV-G-
Figure 2 Targeted-transduction of human pancreatic cell lines by the specific pseudotyped GFP-expressing lentivirus. A) PDAC cell lines
were transduced with lentiviruses packaged into VSV-G-containing envelopes at increasing multiplicity of infection. MOI = 10 corresponds to a
p24 = 100 ng. B) PDAC cell lines were transduced with 100 ng of p24 oncospecific lentiviruses packaged into the 2.2 Sindbis virus glycoprotein-
containing envelopes bound to the antibodies mentioned on the x axis (0.5 μg). The y axis corresponds to the% of transduced cells expressing
the reporter gene GFP analysed by flow cytometry. Each condition has been tested at least in 3 independent experiments. All conditions with
oncospecific lentiviruses are statistically significant (Student’s t test, p < 0.01) compared to negative control condition (ISO) except for PSCA-
targeting viruses. C) Western-blots of PDAC cell lines protein extracts with the antibodies used for the targeted transduction. Anti-GAPDH was
used as a loading control. After quantification of the western blots by densitometry, the levels of protein expression were calculated as a ratio of
GAPDH levels and are shown in a bar graph as a ratio to levels observed in the BXPC3 cell line.
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viruses conjugated with anti-MUC4 were as efficient as the
broad tropism viruses (93% of the signal). Anti-CLDN18
was less efficient to target the CAPAN2 cells since only
about 9% of the VSV-G signal was obtained (Figure 3).
Gene transfer efficiency was further examined in resected
tumors by detection of the luciferase protein by western-
blot (Figure 3C). We used a tumor extract derived fromuntransduced CAPAN2 cells as a negative control
(CTNEG) and a positive control (CTPOS) obtained from a
tumor derived from CAPAN2 cells transduced with a
lentivirus bearing the bicistronic transgene Luciferase-
IRES-ZsGreen. Before the grafts, cells were sorted and at
least 80% expressed the reporter protein ZsGreen. Quanti-
tatively, the levels of luciferase in the positive control were
less than in the tumors transduced with the broad tropism
Figure 3 Anti-MUC4 antibodies bound to modified lentiviruses
drive efficient gene transfer in vivo in CAPAN2 cells. (A) CAPAN2
cells were grafted subcutaneously in the right flanks of immune-
deficient recipient mice. When tumors reached about 100 mm3,
lentiviruses carrying the luciferase reporter gene combined with anti-
MUC4, anti-CLDN18 (PDAC targeting antibodies), anti-HLA (positive
control for the targeted gene transfer), rabbit IgGs (ISO, negative
control for the targeted gene transfer) or packaged into the broad
tropism VSV-G-containing envelope (positive control) were directly
injected in the tumors (n = 3 in each group). Two weeks after virus
injections luciferase signal was measured in anesthetized live animals
with a photon imager apparatus. (B) Quantification of luminescence in
photons/steradiant/s (ph/sr/s) was divided by tumor mass in mg, since
tumor mass could be very different in individuals after resection, and is
expressed as a percentage of VSV-G positive control. Red circles depict
the zones used for quantification (same size for all the mice). The black
arrow points the area measured for background signal determination.
Student’s t tests against the VSV-G condition were statistically different
for ISO (p = 0.04) and CLDN18 (p = 0.05). (C) Western-blot analysis of
luciferase expression in the previous tumor extracts. The negative
control (CTNEG) corresponds to a tumor extract of untransduced
CAPAN2 cells. The positive control (CTPOS) was obtained from a tumor
derived from CAPAN2 cells transduced with a lentivirus bearing the
bicistronic transgene LUCIFERASE-IRES-ZsGREEN. Extracts obtained
from tumors transduced by oncospecific lentiviruses are identified
according to the target cell surface antigen. ISO: rabbit IgGs.
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control however, the luciferase open reading frame (ORF)
was behind the IRES, whereas in the “VSV-G” condition,
the luciferase ORF is first, because different lentivectors
were used. Thus, it was expected to obtain a lower expres-
sion level in the CTPOS. Comparatively, the efficiencies of
transduction seemed very good with MUC4 oncotropic
viruses, and a little less with the HLA and CLDN18 target-
ing lentiviruses. Overall, the western-blot confirmed the
results obtained by direct luciferase activity detection in the
tumors.
To further explore targeted gene transfer in PDAC,
another cell line was tested. First, the MIAPACA2 cells
were modified to stably express the fluorescent protein
tdTomato for the direct follow up of tumor progression
in live animals using the bioimaging system, and the
quantification of tumor growth. In subcutaneous tumors
(Figure 4), the anti-CLDN18 antibody failed to raise the
signal above that of the isotype control. However, anti-
MUC4 conjugated viruses were again almost as efficient
as viruses packaged into the VSV-G-containing envelope
(about 75% of the “VSV-G” signal). This result was
confirmed by using two different anti-MUC4 antibodies.
Thus, in subcutaneous tumors, intra-tumoral injection
of lentiviruses associated with the tumor cell surface
antigen MUC4 seemed efficient enough to test the trans-
fer of a suicide gene.
Targeted transduction of the herpes simplex virus
thymidine kinase gene is toxic in pancreatic cell lines
in vitro and in vivo, in the presence of ganciclovir
Since we produced MIAPACA2 cells stably expressing
the tdTomato fluorescent protein, we first checked that
these cells were sensitive to ganciclovir when expressing
the Herpes Simplex virus thymidine kinase gene. Cells
were transduced with viruses packaged into broad trop-
ism envelopes (from VSV-G), expressing either the GFP
protein (CT) or a bicistronic gene encoding the firefly
luciferase and the Herpes Simplex virus thymidine kin-
ase (LUC-IRES-TK). Cells were treated with increasing
concentrations of ganciclovir and cell viability was
examined 10 days after the treatment (Figure 5A).
Expectedly, cells expressing the thymidine kinase died
in the presence of ganciclovir in a dose-dependent
manner.
TdTomato-MIAPACA2 cells were grafted in the pan-
creas of recipient mice. Tumor growth was monitored
by fluorescence detection for 21 days (Figure 5B).
MUC4-oncotropic viruses or control IgGs-conjugated
viruses were then injected in the intra-pancreatic
tumors. After about 2 weeks, luminescence signals were
very high in the “MUC4” injected mice (Figure 5C),
suggesting efficient gene transfer in the tumor cells
(p = 0.018 with a 2-sided Mann Whitney test against
Figure 4 Luciferase expression driven by MUC4-oncotropic virus co-localizes with fluorescence in tdTomato-MIAPACA2 tumors. (A)
MIAPACA2 cells were modified to express permanently the tdTomato reporter gene, detectable with the photon imager in subcutaneously
grafted tumors (top panel). Lentiviruses carrying the luciferase reporter gene combined with anti-MUC4, anti-CLDN18 (PDAC targeting antibodies),
rabbit IgGs (ISO, negative control for the targeted gene transfer) or packaged into the broad tropism VSV-G-containing envelope (positive control) were
directly injected in the tumors (n = 3 in each group). Three weeks after virus injections luciferase signal was measured in anesthetized live animals with
a photon imager apparatus (bottom panel) and co-localizes only with fluorescent tumor cells. (B) Quantification of luminescence in ph/sr/s was
divided by tumor fluorescence (ph/sr/s) and is expressed as a percentage of VSV-G positive control. Student’s t tests against the VSV-G condition were
statistically different only for ISO CLDN18 (p = 0.05 for both). Red circles depict the zones used for quantification (same size for all the mice).
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Figure 5 Targeted transduction of the Herpes Simplex virus thymidine kinase gene is toxic in vitro and in vivo, in the presence of
ganciclovir. A) MIAPACA2 cells stably expressing the tdTomato protein were transduced with viruses packaged into broad tropism envelopes,
expressing either the GFP protein (CT, dark gray line) or a bicistronic gene encoding the firefly luciferase and the herpes simplex virus
thymidine kinase (LUC-TK, light gray line). Cells were treated with ganciclovir. Cell death was examined 10 days after treatment. Cell
viability was measured by MTS tests. ***: p<0.001 in Student’s t test compared to control condition. B) TdTomato-MIAPACA2 cells were
grafted in the pancreas of recipient mice. After 21 days anti-MUC4-conjugated viruses (MUC4) or control IgGs-conjugated viruses (ISO)
were injected in the intra-pancreatic tumors (n=6 animals in each group). After 36 days, ganciclovir was injected daily for two weeks
(solid red lines). Left panels: fluorescence corresponding to grafted tumor cells the first day of GCV injection (Day 36) and one week after
the beginning of GCV injections (Day 45). Right chart: Quantification of fluorescence signals expressed as a fold increase of fluorescence
detected on day 1. C) Left panels: luminescence signals observed in mice the first day of GCV injection (Day 36) and one week after the
beginning of GCV injections (Day 45). Right chart: Raw luminescence signals are reported as ph/sr/s from the day of virus injection (day
21) to the day of experiment termination (day 45). On day 21, when viruses were injected, we had lost 1 mouse in the MUC4 group
and 2 mice in the ISO group. On day 45, we had only 3 mice in each group. p=0.06 with a 2-sided Mann Whitney test against control
signal, n=3. * p=0.018 with a 2-sided Mann Whitney test against control signal, n=4-5.
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ganciclovir (GCV) daily, and the experiment was termi-
nated by sacrificing the mice 2 weeks after the first in-
jection of GCV. GCV injection induced a drop of
luminescence signal in the “MUC4” mice as soon as
7 days after the beginning of the treatment (Figure 5C).
The signal then remained low, and up to the level of that
of the control mice. Concomitantly, when tumor growth
went on to be about 50 times bigger than at the begin-
ning in the control mice, tumor growth was slowed
down in the “MUC4” mice and reached only about 24-
fold of the initial fluorescence value (Figure 5B, p = 0.06
with a 2-sided Mann Whitney test against control signal,
n = 3, our initial group of 6 mice in each group having
dropped by half because of surgery complications or
tumor development). Mitosis and apoptotic figures were
quantified on tumor sections. While the number of cells
in M phase was not different between tumors, tumors
that had received the oncotropic lentiviruses displayed
higher numbers of apoptotic figures (Figure 6).
Lentiviruses were injected intra-tumorally and there was
still a possibility that they transduced the tumors just be-
cause they were provided locally at a high concentration.
To test this hypothesis, we performed intra-pancreatic
injections of the broad tropism virus and of the MUC4
oncotropic virus in tumor-free mice. After one week, the
broad tropism virus transduction was highly detectable inFigure 6 Mitotic and apoptotic figures on sections from ISO and MUC
injected with ISO-oncotropic control lentivector (A) or with MUC4-oncotro
and apoptotic figures (A) were counted in 2791 (ISO) or 1558 (MUC4) cellsthe pancreas (Figure 7A) but also the virus had leaked to
transduce other tissues such as the liver, the intestine and
surprisingly the region of the testis (Figure 7B). Con-
versely, the MUC4 oncotropic virus did not achieve any
detectable transduction in the pancreas or in any other
site (Figure 7C). After two weeks, the broad tropism viral
transductions were still detectable with higher signals in
the pancreas (Figure 7E) and had been partly cleared from
the liver, but remained and even increased in the gut and
the testis. No new signal appeared in the MUC4 oncotro-
pic virus-injected mice.
Thus intra-tumoral injections of the MUC4 oncotropic
virus appeared to be a very specific way to perform gene
delivery in pancreatic tumors by contrast to a broad
tropism virus, which transduced normal pancreatic cells
and reached tissues distant from the tumor and the
injection site.
Discussion
In this study, we tested for the first time the possibility
to specifically deliver a therapeutic gene into pancreatic
tumor cells using cell surface markers.
Gene transfer with lentiviruses is a very potent ap-
proach of gene therapy since viruses can transduce cells
regardless of their stage in the cell cycle [20]. Previous
studies have reported the possibility to use lentivectors
for gene delivery to pancreatic cancer cells but were4-oncotropic lentivector-injected tumors. Sections from tumors
pic lentivector (B) were stained with hematoxilin. Mitotic figures (M)
(n = 3). **: p = 0.002 with Student’s t test. Original magnification X40.
Figure 7 Oncotargeted transduction of lentiviruses is efficient only in pancreases bearing tumors. Ten μg of p24 lentiviruses carrying the
luciferase reporter gene packaged into the VSV-G-containing envelope (A lateral view, B ventral view) or anti-MUC4-conjugated lentiviruses
(C lateral view) were directly injected in the pancreas of tumor free animals (n = 3 animals in each group). Luciferase signal was visualized after
one week. Luciferase signal intensity was quantified and is reported as mean of Ph/sr/s ± SEM (D). Increased luciferase signal is shown after
16 days in the same animals (E, F: VSV-G and G: MUC4), with signal quantification (H).
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approach might represent a risk of morbidity because
of possible integrations of the viruses in normal cells
(off target transductions). However, viral gene therapy
still holds the promise of oncotargeting gene delivery
sparing the normal cells, thanks to the modified Sindbis
virus glycoprotein developed by Pariente et al. [13] and
used here. This approach offers the possibility to specif-
ically pseudotype the viral particles. We found that
modified Sindbis virus glycoprotein-packaged lenti-
viruses could efficiently transduce the pancreatic cell
lines in vitro. Three pancreatic cell surface antigens were
tested for specific lentiviral gene transfer. The use of
anti-PSCA yielded very poor gene transfer, regardless of
the cell line. This result was disappointing since this
protein was found highly expressed in pancreatic adeno-
carcinoma [21] and anti-PSCA drove efficient gene
transfer in prostate tumors [13]. Interestingly however,
CLDN18 and MUC4 achieved the best results in terms
of efficiency and specificity in vitro and could be suitable
for specific gene transfer in pancreatic tumor cells. To
test this hypothesis, human tumor cells were grafted
under the skin of immune-deficient mice. Therapeuticagent administration by intra-tumoral injections is pos-
sible in pancreatic tumors since it has been performed in
clinical trials with endoscopic ultrasound injections [22].
Moreover, intra-tumoral injection of therapeutic oncotro-
pic lentiviruses might be safer than intra-venous delivery
to limit any systemic toxicity. Anti-MUC4-pseudotyped
viruses carrying the firefly luciferase reporter gene, directly
injected in the tumors yielded, luminescence signals in the
tumors comparable to signals obtained with viruses pack-
aged into the non-specific envelope containing the VSV
glycoprotein, in two different cell lines. In vivo, MUC4
was a more potent antigen than CLDN18 and even than
HLA antigens in the CAPAN2 cells. Remarkably, lumines-
cence appeared confined to the tumors since no signal
was detected elsewhere in the mice, even when the detec-
tion mode was used with very low stringency. This obser-
vation was made previously when the gene transfer
targeting system used here was tested by others [13-15].
Noteworthy, pancreatic injections of viruses in tumor-free
mice led to very interesting observations. First, the broad
tropism virus transduced very efficiently the pancreas and
leaked in other intra-abdominal sites, and even in the
testis. By contrast the MUC4 oncotropic virus showed no
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pancreas, in the absence of tumors, even at the injection
site. Taken together, this set of data suggests that the
oncotropic lentiviral transductions appeared safer and
more specific than VSV-G-driven transductions.
The results with CLDN18 oncotropic viruses were
somewhat disappointing in the in vivo transductions,
considering that the fact that similar results were
obtained for CLDN18 and MUC4 oncotropic viruses
in vitro (Figure 2B). We actually noticed strong signals
one week after virus injections with anti-CLD18 anti-
bodies, but signals had partially disappeared in CAPAN2
and almost totally disappeared in MIAPACA2 cells at
the time of sacrifice, after two weeks (not shown). One
possible explanation could be that fixation of anti-
CLDN18 might interfere with the biological function of
claudin 18 in cancer cells, probably leading to cell death.
Herpes thymidine kinase (TK) in combination with
the pro-drug ganciclovir remains one of the most potent
systems for anticancer gene therapy approach and has
given promising results in a very recent phase I clinical
trial with an adenoviral system [6]. We evaluated the
transfer of the TK gene by MUC4 oncotropic lenti-
viruses injected in orthotopically grafted human pancre-
atic tumor cells. Our experimental strategy was designed
to do both the follow up of tumor growth (by fluores-
cence) and of the virus-infected tumor cells (by bio-
luminescence) in live animals. Importantly and as
observed before, luminescence remained confined to the
tumors when viruses were injected directly in the pan-
creas of the recipient mice. Moreover, GCV treatment
resulted in luciferase signal loss and in slowing down of
the tumor growth. It would be worth now to use this
strategy to examine other PDAC-specific cell surface tar-
gets, and we feel that this study presents the proof of
concept of oncotargeted molecular therapy of PDAC.
There are many ways to improve the system. First,
several targets (cell surface markers) could be used in
concert as well as several rounds of virus injections
could be performed to gain in efficiency. Second, once
the markers have been validated, it is now possible to
use vectors pseudotyped with engineered Sindbis virus
glycoprotein bearing a covalent link with the antibodies.
Indeed, fusion proteins could be produced [23] render-
ing the transduction very potent even in an immune-
competent background. Another attractive option would
be the use of the biotine/avidine combination developed
more recently [24].
Conclusion
Our study outlines for the first time three major con-
cepts: (i) lentiviral transduction of human pancreatic
tumor cells was possible when cells were grafted directly
in the pancreas, (ii) this transduction was achieved witha system targeting the tumor cells with cell surface anti-
gens, sparing the normal cells and (iii) detectable loss of
reporter gene-expressing cells obtained by viral trans-
duction was observed with the TK/GCV anticancer sys-
tem. Moreover, the approach presented here appeared to
be a safer, much more specific and an as efficient way to
perform gene delivery in pancreatic tumors, in compari-
son with a broad tropism lentivirus. Importantly, we
have developed an orthotopic graft model of human
PDAC allowing the quantification of tumor growth and
the co-localization of oncospecific targeting with direct,
costless and non invasive procedures. Future improve-
ment of this gene therapy approach includes the identifi-
cation of other potent cell surface markers, the use of
combinatory cell surface markers for specific gene trans-
fer and the development of oncotropic envelopes stable
in immune competent background.
Methods
Animals, pancreatic cell lines and antibodies
The NOD/Shi-SCID IL2Rγnull mice were produced and
housed in the University Bordeaux Segalen animal
facility, according to the rules and regulations governed
and enforced by the Institutional Animal Care and Use
Committee. The animal facility institutional agreement
number is A33063916. Animals were included in proto-
cols between 6 and 8 weeks old. Mice were monitored
weekly for body weights and were also examined for
aspect and behavior during the time-course of the experi-
ments. No changes were noticed except otherwise
indicated. The PDAC PANC1 and MIAPACA2 cell lines
were purchased from the ATCC (American Type Culture
Collection, Molsheim, France). CAPAN2 and BXPC3
were kindly provided by Joel Tardive-Lacombe (INSERM
U624, Marseille, France). The CAPAN2 and BXPC3 cells
were maintained in RPMI (Invitrogen) with 10% Fetal
Calf Serum (FCS, Invitrogen) and Penicillin/Strepto-
mycin 1/100 (Invitrogen), the PANC1 and MIAPACA2
were cultured in DMEM with 10% FCS and Penicillin/
Streptomycin 1/100.
The tdTomato-MIAPACA2 cell line was produced by
transduction of the MIAPACA2 cells with a lentivirus
carrying the tdTomato reporter gene (PGK-tdTomato,
see below). Transduced cells were sorted by a BD FACS
ARIA cell sorter (BD Biosciences, France).
The antibodies used in this study were purchased as fol-
lows: anti-HLA, anti-MUC4, rabbit IgGs (SIGMA ALDRICH,
Lyon, France), anti-CLDN18 (GenWay, San Diego,
CA-USA), anti-PSCA (Abcam, Paris, France), anti-PSCA
(SIGMA ALDRICH, Lyon, France).
Vector construction, production and transduction of cells
pPGK-tdTomato lentiviral plasmid was constructed by
transferring the tdTomato gene from p-tdTomato
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Sin-cPPT.PGK.WPRE lentiviral plasmid (gift from Dr.
Trono, Lausanne, Switzerland). LUCIFERASE-IRES-TK
lentivirus plasmid was obtained by replacing GFP from
pLOXgfp-IresTK (Addgene Plasmid # 12243, Cambridge,
MA-USA) with the firefly-Luciferase gene (Clontech).
Cloning details can be provided upon request. A
LUCIFERASE-IRES-ZsGreen lentivirus plasmid was
obtained as follows: the fireflyLuciferase gene was cloned
into the pIRES2-ZsGreen1 vector (Clontech, Saint Germain
en Laye, France). All lentiviral vectors were produced by
calcium phosphate mediated triple transient transfection of
293 T cells with one of the vector transfer constructs, the
packaging construct pCMVΔ8.91 (gift from Dr. Verma, La
Jolla, CA-USA) and either VSV-G construct psPAX2 (gift
from Dr. Trono) or 2.2 plasmid (a gift from Drs. Chen and
Morizono, coding for a modified Sindbis virus glycoprotein
envelope, Los Angeles, CA-USA). The viruses produced
were concentrated by ultracentrifugation (through a 10%
sucrose cushion). The capside protein p24 titrations were
determined as already described [25].
Analysis of lentiviral transduction by flow cytometry
FACS analyses were performed on a FACScalibur flow cyt-
ometer (BD biosciences, Le Pont de Claix, France) on
trypsinized cells 3–5 days after transduction. Transduc-
tions were carried out on 5.104 cells in 48-well plates.
Virus mixes containing 100 ng of p24 were prepared in
250 μl of serum-free medium with antibodies at 0.5 μg/ml.
Percentages of GFP-positive cells were determined using
CellQuest software (Becton Dickinson, Le Pont de Claix,
France) in comparison with non transduced cells, after
counting of cells in the FL-1 channel.
Western-blots
Protein extracts were prepared in RIPA buffer and
processed for western blotting. Membranes were incu-
bated with the targeting antibodies or a rabbit anti-
luciferase antibody (AbCam, Paris, France). Rabbit
anti-GAPDH antibody (Cell Signaling Technologies,
Saint-Quentin-en-Yvelines, France) was used to assess
equal loading of the samples. Primary antibodies were
detected with specific anti-rabbit- or anti-mouse-IgG-HRP
(Cell Signaling Technologies). Proteins were visualized
using the ECL detection system (Amersham Pharmacia
Biotech, Orsay, France). Quantification by densitometry
was performed with the ImageJ software.
Histology
Tumors were fixed in 10% NBF, embedded in paraffin
and processed by routine histology procedures. The pro-
portion of mitosis/total cells or apoptosis/total cells was
evaluated after Hematoxilin staining by direct counting
on pictures taken at X40 magnification.In vitro cell proliferation assay
To test the effect of Herpes Simplex virus thymidine
kinase on the tdTomato-MIAPACA2 cell viability in the
presence of ganciclovir (GCV, SIGMA ALDRICH, Lyon,
France), cells were first transduced with a lentivirus
bearing the LUCIFERASE-IRES-TK transgene (see
above). Cells were plated at 3.103 cells per well in
96-well plates. The day after, increasing doses of GCV
(0-100 μM) were applied and cells were kept in culture
for 10 days. Each point was done in quadruplet. The
experiments were carried out 2 times. Cells were washed
with PBS and treated with MTS (3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl) - 2H-
tetrazolium) solution (Promega, Charbonnières, France)
for 1.5 h to determine cell viability by reading optical
densities (OD) at 490 nm. Results are expressed as cell
viability: ODtreatedð Þ=ODnontreatedÞ  100:
Bioluminescent imaging of pancreatic adenocarcinoma
xenografts
For subcutaneous xenografts, groups of 3–5 mice were
anesthetized with isoflurane. 8.105 to 106 cells in 100 μl
medium were injected in the right flanks. When tumors
reached about 100–150 mm3, diverse combinations of
viruses (described in the result section) were injected in
the tumors or directly in tumor-free pancreases in single
injections. Briefly, 7 μg p24 of lentivirus were mixed,
when necessary, with 5 μg of antibody and incubated
5 min at room temperature in 60 μl serum free-medium.
Tumors were monitored for luciferase expression on a
weekly basis as follows. 150 mg/kg of D-Luciferin
(Interchim, Montluçon, France) was injected intraperi-
tonally. After 10 min, mice were anesthetized by isoflurane
and placed into a photon bioimager (BIOSPACE LAB,
Paris, France) for about 20 min to acquire luminescence
images. Signals were quantified with the M3Vision
software (BIOSPACE LAB).
For orthotopic xenografts, groups of 4–6 mice were
anesthetized with isoflurane. Pancreases were exposed
and 8.105 of tdTomato-MIAPACA2 cells in 40 μl
medium were injected directly in the pancreas. Tumor
growth was monitored weekly with the bioimager using
the fluorescence detection setting (Acquisition mode:
FLI integration at 22 ms per frame, Excitation = 520 nm,
Background = 480 nm, Emission = 570 nm, Filter cut off
= 570 nm Illumination: 100%). When signals were easily
detectable (after 21 days), mice were anesthetized with
isoflurane and injected with the lentiviruses. Ten μg p24
of lentiviruses were incubated 5 min at room
temperature in 60 μl serum free-medium with 5 μg of
antibody and injected intra-tumorally as described
above. Luciferase expression and fluorescence signal
were monitored weekly. Two weeks after virus injec-
tions, mice were treated daily with GCV (1 mg/mouse).
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Transduction efficiencies in vitro are expressed as mean
% of transduced cells ± SD. MTS assay results and
in vitro transduction results are expressed as mean ± SD.
Luminescence quantifications performed in vivo are
expressed as mean ± SEM. Statistical tests were per-
formed with Student’s t tests or with a 2-sided Mann
Whitney test for intra-pancreatic luciferase detections
and tumor growth.
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